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Abstract 
Startling reports described the paradoxical triggering of human mitogen activated protein 
kinase pathway when a small molecule inhibitor specifically inactivates the BRAF V600E 
protein kinase but not wt-BRAF. We performed a conceptual analysis of the general 
phenomenon "activation by inhibition" using bacterial and human HtrA proteases as models. 
Our data suggest a clear explanation that is based on the classic biochemical principles of 
allostery and cooperativity. Although sub-stoichiometric occupancy of inhibitor binding sites 
results in partial inhibition, this effect is overrun by a concomitant activation of unliganded 
binding sites. Therefore, when an inhibitor of a cooperative enzyme does not reach saturating 
levels, a common scenario during drug administration, it may cause the contrary of the desired 
effect. The implications for drug development are discussed. 
 
Significance Statement 
Small molecule inhibitors of enzymes are commonly derived from native ligands and represent 
invaluable and extensively applied tools in chemical biology. In addition to the well-known 
issue of selectivity, paradoxical curiosities were described over decades that have wide 
implications in drug discovery and treatment. Of particular interest are observations where low 
concentrations of inhibitors may activate their targets instead of causing partial inhibition. Our 
conceptual analysis explains the general phenomenon of "activation by inhibition" as a ligand-
induced transition between the T state and the R state in the classic Monod-Wyman-Changeux 
model of activation, in which the inhibitory ligand acts as an activator. 
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Introduction 
The activity of complex enzymes is precisely regulated by sophisticated molecular 
mechanisms that are described by the fundamental biochemical principles of allostery, 
cooperativity and oligomerization. Allostery is defined as the interaction of binding sites at a 
distance, allowing for the regulation of catalytic activity. Thus, a ligand bound to one site 
affects the affinity of another site for the same or a different ligand by inducing transitions 
between distinct conformational states. In ‘classic’ biochemistry, the couplings of binding sites 
are differentiated into functional interactions. Identical binding sites and homotropic ligands 
are the basis of cooperativity while a more general functional interaction of individual binding 
sites and heterotropic ligands is known as allostery. Allosteric effects may be observed 
between individual domains of monomeric proteins or between protomers of oligomeric 
protein complexes. Moreover, the allosteric switch between the resting and the active 
conformations can be accompanied by rather dramatic events such as changes in oligomeric 
states. While well-known studies have been performed on e.g. hemoglobin, the oxygen binding 
protein of red blood cells, or aspartate transcarbamoylase, a key enzyme in pyrimidine 
synthesis (1, 2), recent evidence suggests that prokaryotic DegP represents an exceptionally 
suitable model for addressing the underlying mechanisms of allostery, cooperativity and 
activation by oligomerization (3, 4).  
The heat shock factor DegP functions as a conformation-specific protease/chaperone complex 
that channels substrates into repair, assembly or degradation pathways (3, 5). DegP is a cage-
forming protease, where the size of the cage is determined by the number of assembled 
trimeric subcomplexes. DegP protomers consist of a serine protease domain and two C-
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terminal PDZ domains. PDZ domains are protein modules that bind the C-terminal 3–4 
residues of target proteins (6). Recent studies revealed how ligands of PDZ1 domain serve as 
allosteric activators inducing positive cooperativity by triggering conformational changes and 
large structural rearrangements including switches between various oligomeric states where 
hexamers represent the resting state while higher oligomers represent the active state (7-10). 
DegP has two binding sites per protomer, the catalytic site and the peptide binding site of the 
PDZ1 domain that are linked by an allosteric circuit. In addition, activation domains that are 
shared between adjacent protomers mediate concerted activation of the catalytic sites within 
the trimeric subcomplexes. This architecture is the basis of positive cooperativity where ligand 
binding to one binding site of one protomer not only increases the affinity of ligands for the 
second site within the same protomer but in addition increases the affinity for ligand binding to 
the neighboring protomer. 
 
Results 
These mechanistic considerations suggested a hypothesis where sub-stoichiometric binding of 
a substrate-derived inhibitor would activate DegP instead of causing partial inhibition. This 
behavior can be explained because the ligand-bound active site is structurally connected to 
neighboring protomers and their unoccupied active sites and PDZ1 domains. Conceptually, 
these allosteric interactions should cause increased affinity of unoccupied sites for their ligands 
ultimately resulting in increased enzymatic activity. To initially test this model of regulation, 
we used the synthetic substrate SPMFKGV-pNA to measure DegP activity in combination 
with the peptidic boronic acid inhibitor DPMFKLV-B(OH)2 that targets the active site Ser 
residue (4, 11). The steady-state rate of substrate hydrolysis varied sigmoidaly as a function of 
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the substrate concentration, characteristic of substrate-induced allostery (SI Appendix, Fig. 
S1A). Kinetically, each time-course showed a significant lag-phase before activation of the 
proteolytic activity while increases in DegP concentration reduced both the length of the lag-
phase and both the steepness and extent of the activation (SI Appendix, Fig. S1A). This 
observation is consistent with a previously-established mechanism in which DegP undergoes 
large changes in oligomeric state i.e. from the resting state hexamer, which dissociates into 
trimers and reassembles to form active 12-mer and even 24-mer assemblies (12, 13). This 
drastic change in oligomeric states normally occurs in response to the binding of substrate to 
the active site or the binding of allosteric peptides to the PDZ1 domain. The presence of the 
lag-phase (SI Appendix, Fig. S1A) reflects the rather slow interconversion of DegP between 
the resting conformation and the allosterically-activated states due to the absence of a 
heterotropic allosteric activator binding to the PDZ1 domains and also the relatively weak 
binding of the peptide substrate (SPMFKGV-pNA) used here. Note that SPMFKGV-pNA does 
not bind to the PDZ domain, because this substrate does not contain a C-terminal carboxylate 
which is essential for binding (6). 
 
Activation by sub-stoichiometric inhibition. Binding of DPMFKLV-B(OH)2 was 
investigated using ITC. Measurements indicated a two-step binding mode of the inhibitor to 
DegP, expected for a cooperative enzyme. The weaker-binding phase (Kd = 6 µM) likely 
reflects the binding of the inhibitor to the resting state conformation, followed by a second, 
much tighter binding event (Kd = 33 nM) reflecting inhibitor binding to the fully activated 
proteolytic sites (Fig. 1A). Binding of the inhibitor to the active site of a cooperative enzyme is 
expected to promote the conformational switch to a tighter binding conformation, thereby 
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resulting in activation of the enzyme at sub-stoichiometric concentrations. To quantify 
activation by sub-stoichiometric inhibition, DegP was treated with various concentrations of 
DPMFKLV-B(OH)2, ranging from 1 nM to 10 µM, before measuring DegP activity using 
SPMFKGV-pNA as a substrate. In agreement with our hypothesis, DegP activity is increased 
by up to 3-fold at sub-stoichiometric concentrations of the inhibitor (Fig. 1B). To show that the 
observed activation is not substrate-specific, the proteolytic assays were repeated using the 
periplasmic domain of the antisigma factor RseA from E. coli as a substrate (14), revealing 
similar effects (SI Appendix, Fig. S1B). As activation of DegP is usually connected with a 
change in oligomeric state, DPMFKLV-B(OH)2 was titrated to DegP and the oligomeric state 
was determined by size exclusion chromatography and chemical crosslinking. Interestingly, a 
switch from hexamer to dodecamer was only observed at above 2-fold excess of inhibitor, i.e. 
concentrations where DegP is inhibited (Fig. 1C, SI Appendix, Fig. S1C), suggesting that 
activation by sub-stoichiometric inhibition can occur in the hexamer. Control experiments 
show that the catalytically inactive DegP S210A mutant does not bind DPMFKLV-B(OH)2, as 
determined by ITC (SI Appendix, Fig. S1D), and changes of oligomeric states do not occur 
even at high inhibitor concentrations (SI Appendix, Fig. S1C). To rule out that the observed 
activation results from unspecific biochemical effects such as aggregation (15), we applied a 
non-binding inhibitor derivative carrying a (D)-configuration at the valine boronic acid residue 
that had no or only minor effects on DegP activity (SI Appendix, Fig. S1E).  
 
Activation by sub-stoichiometric inhibition in combination with allosteric activators. 
DegP is allosterically activated by the C-termini of misfolded proteins which bind to its PDZ1 
domain (Fig. 1D) (16). We therefore tested whether allosteric peptides would modulate 
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activation by sub-stoichiometric inhibition. Two allosteric peptides displaying a 100-fold 
difference in affinity towards DegP's PDZ1 domain were selected. The Kd values for the 
binding of DYFGSALLRV, corresponding to the C-terminus of E. coli EfeB (17) and the 
synthetic peptide DNRDGNVYFF that was characterized previously (9) were 1.2 µM and 135 
µM, respectively (SI Appendix, Fig. S2A, S3A). Titration experiments indicated sequence 
specific differences in the potency of allosteric activation ranging between about 10 and 3-fold 
when using SPMFKGV-pNA as a substrate (Fig. 2A, SI Appendix, Fig. S2B, S3B). To 
subsequently test the combined effects of allosteric activators and inhibitor, the concentrations 
of the two allosteric peptides, DYFGSALLRV (2.5 µM) and DNRDGNVYFF (500 µM), were 
kept constant. Subsequent titration of inhibitor caused an up to 4-fold further activation of 
DegP at sub-stoichiometric inhibitor concentrations (Fig. 2A, SI Appendix, Fig. S2B, S3B). 
Similar results were obtained using RseA of E. coli as a substrate. DPMFKLV-B(OH)2 was 
titrated to DegP in the presence of 2.5 and 50 µM of the allosteric activator DYFGSALLRV 
and degradation of RseA was followed by SDS PAGE at various time points. Again, activation 
was observed at sub-stoichiometric levels of inhibitor (Fig. 2B). Similar data were obtained 
using DNRDGNVYFF (SI Appendix, Fig. S3C). Furthermore, analysis of kinetic data 
indicated that the Ki of the inhibitor changed in the presence of the PDZ activator from 28 nM 
to 0.6 nM for DYFGSALLRV and to 20 nM for DNRDGNVYFF, respectively (compare Fig. 
1B, Fig. 2A, SI Appendix, Fig. S3B). Moreover, to demonstrate that the detected activation 
coincided with increased affinity of allosteric peptides, ITC experiments were performed at 
various inhibitor concentrations. As expected, the Kds of both peptides showed 6-fold higher 
affinities, i.e. for DYFGSALLRV from 1.2 µM in the absence of inhibitor to 0.2 µM in its 
 8 
presence and for DNRDGNVYFF from 135 µM to 23 µM, respectively (SI Appendix, Fig. 
S2A, S3A).  
 
Activation by sub-stoichiometric inhibition in vivo. To further substantiate our results, we 
tested whether activation at sub-stoichiometric concentrations of inhibitor occurred in living 
cells. For these assays, we used the experimental system that led to the discovery of the degP 
gene (Fig. 2C) (18). When a tsr-phoA fusion is expressed in E. coli, the Tsr-AP hybrid protein 
is cleaved near the fusion joint mainly by DegP but only marginally by other cell envelope 
proteases (SI Appendix, Fig. S4). Therefore, these cells represent a suitable reporter system to 
measure DegP activity in vivo. Growing cells expressing the plasmid-derived tsr-phoA fusion 
and native chromosomal degP were treated with DPMFKLV-B(OH)2 at various concentrations 
ranging between 50 nM and 100 µM. Subsequently, proteolytic processing of the Tsr-AP 
hybrid protein by DegP was determined by Western bloting (Fig. 2D). The pattern of Tsr-AP 
bands indicated that at high inhibitor concentrations (25 - 100 µM), proteolytic processing of 
Tsr-AP was reduced because DegP is inhibited. At intermediate inhibitor concentrations (0.5 - 
5 µM), processing of Tsr-AP was increased, while at lower concentrations of inhibitor (0.13 - 
0.05 µM) processing of Tsr-AP was comparable to the DMSO control. Densitometry of the 
signal intensity of the Tsr-AP band relative to the DMSO control indicated an up to 2.5-fold 
increase in DegP activity at 2.5 and 5 µM inhibitor concentrations, respectively (note that the 
reduced amount of DegP at low inhibitor concentrations is likely the result of autoproteolysis 
caused by its activation). Therefore, the in vivo reporter system supported the results obtained 
by biochemical assays using purified proteins. These data also showed that even moderate 
activation of DegP can significantly affect processing of target proteins in vivo. 
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Activation by inhibition in human HTRA1. To demonstrate that activation by inhibition is 
not a phenomenon that is specific to the bacterial enzyme DegP and its unique structural 
properties, we tested the established model using human HTRA1 for which X-ray 
crystallography has shown that DPMFKLV-B(OH)2 binds to the active site in a canonical 
manner (4). While HTRA1 shares structural and functional features with DegP, such as a 
trimeric arrangement of protomers and the conserved activation domain, it differs in several 
aspects, such as surface accessible active sites and a mode of activation that is not strictly 
coupled to changes in the oligomeric state.  
ITC measurements of DPMFKLV-B(OH)2 binding to HTRA1 indicated a Kd of 0.8 µM (SI 
Appendix, Fig. S5A). To test whether HTRA1 can be activated by DPMFKLV-B(OH)2, we 
performed proteolytic digests using its native substrate tau and various concentrations of 
inhibitor. An up to 15-fold increase in HTRA1 activity was observed in the presence of the 
inhibitor (Fig. 3). However, in contrast to DegP, the highest activation of HTRA1 was not 
observed at sub-stoichiometric concentrations of the inhibitor, but at 20-fold excess. This 
effect might be best explained by the 24-fold lower affinity of the inhibitor for HTRA1. To 
overcome this limitation, HTRA1 was pre-incubated with an allosteric ligand of the PDZ 
domain, SYAAWIDVEDL (Kd=32 µM, SI Appendix, Fig. S5B) at concentrations 3-fold 
below (10 µM) and 5-fold above (150 µM) its Kd. Subsequently, DPMFKLV-B(OH)2 was 
titrated to determine the effects of the inhibitor on HTRA1's activity. At both concentrations of 
the allosteric PDZ domain ligand SYAAWIDVEDL, HTRA1 was activated by the inhibitor up 
to 7-fold and 10-fold, respectively (Fig. 3, SI Appendix, Fig. S5C). As expected,  in the 
presence of 150 µM SYAAWIDVEDL, the inhibitor concentrations where highest activation 
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could be observed shifted from 20 µM to 1-2 µM. In agreement with these considerations, the 
presence of the allosteric activator caused stronger inhibition at high inhibitor concentrations. 
In addition, ITC measurements revealed, in a concentration-dependent manner, an up to 4-fold 
increase of the affinity of the allosteric peptide in the presence of the inhibitor, i.e. from 32 to 8 
µM (SI Appendix, Fig. S5B). 
 
Discussion 
Ligand-derived synthetic inhibitors of enzymes are widely used in basic research and as drugs. 
For inhibitors interacting with single binding sites of monomeric enzymes, dose-response 
correlations are hyperbolic. The response of the enzyme system to inhibition changes 
fundamentally when an enzyme has multiple binding sites that are allosterically connected. 
Here, regulation of activity is more complex and can therefore cause effects that may seem 
paradoxical at first sight. HtrA proteases such as DegP belong to the S1 family of serine 
proteases, prominent members of which include e.g. trypsin, chymotrypsin, thrombin and 
elastase. The latter are typically activated by zymogen conversion. This process involves 
proteolytic processing of N-terminal segments stabilizing conformations via as disorder-order 
transition of the activation domain comprising loops L1, L2 and LD. As the formation of the 
active site is conformationally linked with binding of the newly formed N-terminus into a 
preformed pocket, allostery is an integral part of the activation mechanism of these classic 
proteases (19). Even though activation of DegP does not include zymogen processing, the 
principles described above are conserved. However, the molecular mechanisms regulating 
DegP are more complex. Its loop LD reaches over from an adjacent protomer and the 
activation domain is extended by loop L3 and PDZ domain 1 to sense allosteric ligands of the 
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PDZ domain. Moreover, activation by PDZ ligands is coupled to oligomer conversion, i.e. 
from the resting hexamer to active larger oligomers (9). The events triggered by a strong active 
site ligand such as DPMFKLV-B(OH)2 involve the same elements, the interaction of which 
proceeds in reverse order, i.e. initial interaction of the ligand with the substrate specificity 
pockets and loop L2 triggers the rearrangement of loops L1 and LD* as well as of loop L3 
leading to a structural rearrangement within the PDZ domain and a concomitant increase of 
affinity for its ligands. Therefore, high concentrations of the inhibitor have the same effect as 
allosteric ligands of the PDZ domain, i.e. triggering the conversion of hexamers into larger 
oligomers. Together, these allosteric communications across protomers result in the structural 
rearrangement of substrate-binding pockets, proper positioning of the catalytic triads and 
formation of the oxyanion holes in structurally connected active sites and ultimately in positive 
cooperativity. These processes can be considered as a ligand-induced transition between the T 
state and the R state in the classic Monod-Wyman-Changeux model of activation, in which the 
inhibitory ligand acts as an activator (20) (Fig. 1D). Therefore, activation does not require 
occupation of all allosteric sites. 
Our model of activation of an enzyme by sub-stoichiometric occupancy of an inhibitor is 
reminiscent of other  inhibitor activated systems. One prominent example is the activation of 
the mitogen activated protein kinase pathway when wild type BRAF is targeted by inhibitors 
such as PLX4032 (21). The paradoxical result has been readily explained by inhibitor-driven 
dimerization with unliganded CRAF causing allosteric disruption of autoinhibition and 
transactivation of CRAF leading to increased pathway activity (22). Therefore, the BRAF 
PLX4032 - unliganded CRAF complex represents another example of activation by sub-
stoichiometric inhibition. Consistently, similar effects are observed with kinase-dead mutants 
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of BRAF (23). Moreover, additional allosteric events involving RAS-RAF interactions that are 
not RAS allele specific may come into play (22, 24), promoting additional activation and are 
thus comparable to those observed with allosteric peptides and HTRA1 and DegP. A similar 
example involving small molecule modulators of mammalian kinases describes activation by 
sub-stoichiometric inhibitor concentrations of PERK, a kinase of the unfolded protein response 
of the ER (25). It seems that this mode of regulation is widespread. For  example, low ratios of 
the inhibitors maleate and N-phosphonacetyl-(L)-aspartate to aspartate transcarbamoylase 
cause an increase in enzymatic activity (20, 26). In addition, an engineered E. coli lipoprotein 
containing a hydrophobic C-terminus displayed similar concentration-dependent pattern of 
activation and inhibition of DegP as DPMFKLV-B(OH)2, however the binding site of the 
lipoprotein-derived inhibitor and thus the underlying molecular mechanism remain to be 
elucidated (27).  
The molecular mechanisms described here have wide implications for drug development. If an 
inhibitor that targets a cooperative enzyme is not equally distributed across all tissues, 
reflecting the well-known problem of bioavailability, the inhibitor will be efficient in tissues 
where distribution is good but it will activate the target protein in tissues where concentrations 
are low causing the opposite of the desired effect. Thus, allosteric effects are not only 
important for basic research but they have also considerable importance for clinical 
applications. In general, our work supports the notion that a careful consideration of classic 
biochemical principles is likely to significantly reduce side effects and failed efforts in drug 
discovery (28). 
 
Materials and Methods 
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The synthetic substrate SPMFKGV-pNA of DegP and the peptidic boronic acid inhibitor 
DPMFKLV-B(OH)2 were prepared and used as described (4, 11). The cell based assays of DegP 
activity employing a Tsr-AP hybrid protein were done as described (18). Methods for protein 
purification and ITC measurements followed previously described protocols. They are described in 
detail in the SI Appendix, which includes materials and methods and figures. 
 
Data Availability 
All data are included in the manuscript and supporting information. 
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Figure legends 
Fig. 1. Inhibition of DegP by DPMFKLV-B(OH)
2
 A) ITC thermogram of binding of DPMFKLV-
B(OH)
2
 inhibitor to wt DegP. 400 µM inhibitor was titrated into the sample cell containing 40 μM 
DegP. K
d
s of the two distinct binding steps are indicated. B) Kinetic parameters of DegP (1 µM) 
activity in the presence of the DPMFKLV-B(OH)
2
 concentration indicated using the chromogenic 
substrate SPMFKGV-pNA (500 µM). Error bars = standard deviation of experimental data (n=3). 
Data were fitted to MWC model as described in supplementary information. L, equilibrium constant 
T/R in the absence of ligand; K
i
,  affinity of the inhibitor to activated DegP; K
R
, dissociation constant 
for substrate binding to activated DegP; v/[E]
0
,  maximum turnover rate for the activated DegP 
species; parenthesis, 95% confidence limit of the fit. C) SEC analysis of DegP (100 µM) 
preincubated with ratios of DPMFKLV-B(OH)
2 
indicated. Retention volumes and size (kDa) of 
calibration proteins thyroglobulin (669 kDa), ferritin (440 kDa) and aldolase (158 kDa) are indicated 
(left). Activity of eluted DegP fractions was determined using 500 µM SPMFKGV-pNA as substrate 
(right). Error bars indicate standard deviation (N=3). D) Cartoon of core allosteric mechanism. The 
T-state is the inactive hexamer. It exists in equilibrium with the dissociated trimers (R-state) which is 
competent to bind either substrate (S) or inhibitor (I) to the active site. Although the equilibrium in 
the absence of S or I lies towards the T-state (i.e. K
1
 is small) the binding of S or I pulls the 
equilibrium towards the R-state by thermodynamic coupling. Alternatively, the inactive T-state binds 
activator to the PDZ1 domains moderately but the R-state PDZ1 domains bind activator more tightly 
(i.e. K
RA
>>K
TA
) leading to activation, as once in the R-state it can bind S or I. 
 
Fig. 2. Activation of DegP by substoichiometric inhibition A) Activity of DegP (1 µM) using 
chromogenic SPMFKGV-pNA (500 µM) as a substrate in the presence of various (left) or fixed  
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(right) concentrations of DYFGSALLRV (2.5 µM, corresponding to 2-fold of K
d
) and various 
concentrations of the inhibitor DPMFKLV-B(OH)
2 
(Inh). Error bars indicate standard deviation of 
experimental data (N=3). Data were fitted to MWC model as described in supplementary 
information. L, equilibrium constant between T and R conformations in the absence of ligand; K
R
, 
dissociation constant for substrate binding to activated DegP; K
i
,  affinity of the inhibitor to activated 
DegP; K
TA
 and K
RA
 are the dissociation constants for the interaction between activator and the T-
state conformation, and R-state conformation, respectively; K
i2,
 affinity of the activator for the active 
site; v/[E]
0
 is maximum turnover rate for the activated DegP species; parenthesis, 95% confidence 
limit of the fit. B) Representative images of the digestion of the periplasmic domain of RseA (20 µM) 
by DegP (1 µM) in the presence of fixed concentrations of DYFGSALLRV (2.5 and 50 µM) and 
concentrations of DPMFKLV-B(OH)
2
 indicated (upper panel). **, RseA cleavage products. 
Quantification of DegP activity using the signal intensity of RseA relative to the DMSO control 
(lower panel). Error bars indicate standard deviation (N=3). C) DegP activity in vivo. Cartoon of cell-
based DegP reporter assay. Alkaline phosphatase (AP) is tethered to the N-terminal 164 amino acids 
of Tsr protein. DegP cleaves the Tsr-AP hybrid protein near the fusion joint. D) Inhibitor mediated 
activation of DegP activity in vivo. E. coli cells expressing the tsr-phoA fusion were grown ON at 
30°C in rich medium with either DMSO (2%) or various concentrations of DPMFKLV-B(OH)
2
. 
Whole cell extracts of equivalent number of cells were subjected to SDS-PAGE and Western blotting 
using antibodies against AP. *, Tsr-AP degradation products. Additional Western blots of the same 
samples using MBP-DegP antibodies (lower panel). Quantification of DegP activity using the signal 
intensity of Tsr-AP band relative to the DMSO control (upper panel). Error bars indicate standard 
deviation (N=3). 
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Fig. 3. Activation of HTRA1 by substoichiometric inhibition Proteolysis of Tau (10 µM) by 
HTRA1 (1 µM) in the absence or presence of the fixed concentrations of the allosteric peptide 
SYAAWIDVEDL (10 µM and 150 µM) and various concentrations of the inhibitor DPMFKLV-
B(OH)
2
 (Inh) after 5 h incubation at 37°C (left panel). Quantification of Tau signal intensity using 
densitometry (N=3) relative to the DMSO control, error bars indicate standard deviation (right panel). 
An additional 2 h time point of tau digests is shown in Fig. S5C.  
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